Ruxolitinib treatment in patients with polycythemia vera reduces JAK2 variant allele frequency and improves symptom burden and hematocrit control
Therapeutic Advances in Hematology
Published online on March 24, 2026
Abstract
Therapeutic Advances in Hematology, Volume 17, January-December 2026.
Background:In RESPONSE/RESPONSE-2, ruxolitinib was superior to best available therapy (BAT) in patients with polycythemia vera (PV).Objective:Report a post hoc pooled RESPONSE/RESPONSE-2 analysis.Design:RESPONSE/RESPONSE-2 were randomized, open-label ...
Background:In RESPONSE/RESPONSE-2, ruxolitinib was superior to best available therapy (BAT) in patients with polycythemia vera (PV).Objective:Report a post hoc pooled RESPONSE/RESPONSE-2 analysis.Design:RESPONSE/RESPONSE-2 were randomized, open-label ...